Primary hyperoxaluria is a rare inherited condition where the liver produces excessive amounts of a substance called oxalate, leading to recurrent kidney stones, progressive kidney damage, and in severe cases, life-threatening complications affecting multiple organs throughout the body.

Understanding Treatment Goals and Options for Primary Hyperoxaluria

When someone receives a diagnosis of primary hyperoxaluria, the focus immediately shifts to managing a complex condition that requires lifelong attention and care. The main goals of treatment are to reduce the production of oxalate in the body, prevent the formation of calcium oxalate crystals and kidney stones, preserve kidney function for as long as possible, and maintain quality of life. Because primary hyperoxaluria is a progressive disease, early diagnosis and prompt treatment can make a significant difference in outcomes.^[1]

Treatment approaches vary considerably depending on which type of primary hyperoxaluria a person has, how advanced their disease is, their age at diagnosis, and how their body responds to specific therapies. Type 1 primary hyperoxaluria, which accounts for approximately 80 percent of cases, tends to be the most severe form and often requires the most intensive management. Types 2 and 3 each represent about 10 percent of cases and may follow a somewhat different course.^[1]

The landscape of treatment has evolved significantly in recent years. While standard approaches based on maintaining high fluid intake and using specific medications remain important, new therapies targeting the underlying biochemical problems have emerged. Clinical trials continue to investigate innovative approaches, including advanced RNA-based therapies, with the goal of preventing disease progression and improving outcomes for people living with this challenging condition.^[3]

Standard Conservative Treatment Approaches

The foundation of managing primary hyperoxaluria, regardless of type, is a strategy called hyperhydration—drinking very large amounts of fluid throughout the day and night. This approach works by diluting the concentration of oxalate in the urine, which reduces the likelihood that oxalate will combine with calcium to form crystals and stones. The amount of fluid needed is substantial: patients often need to consume enough water to produce 2 to 3 liters of urine per day, sometimes even more depending on their age, weight, and disease severity.^[3]

Maintaining this level of hydration presents significant practical challenges. Young children may require a gastrostomy tube—a feeding tube inserted through the abdominal wall directly into the stomach—to ensure they receive adequate fluids, especially during sleep. Older children and adults experience frequent interruptions at school or work for bathroom breaks, disrupted sleep from nighttime urination, and difficulty participating in activities where access to fluids and bathrooms may be limited. Despite these burdens, consistent hyperhydration remains one of the most important tools for preventing stone formation and protecting kidney function.^[17]

Alongside hyperhydration, doctors typically prescribe medications to help reduce stone formation. Potassium citrate is commonly used because citrate binds to calcium in the urine, preventing it from combining with oxalate to form stones. This medication needs to be taken several times daily, adding to the treatment burden. Some practitioners also use orthophosphate preparations, though these are less commonly prescribed.^[12]

For patients with primary hyperoxaluria type 1, pyridoxine (vitamin B6) represents an important treatment option for certain individuals. Pyridoxine works by supporting the activity of the deficient liver enzyme, helping it function more effectively despite the genetic mutation. However, this therapy is only effective in patients who have specific types of genetic mutations—typically certain missense mutations that affect how the enzyme is made or where it is located in the cell. When pyridoxine works, it can dramatically reduce urinary oxalate levels, sometimes bringing them close to normal. The vitamin is given in high doses, far exceeding normal dietary amounts, under careful medical supervision.^[9]

Not all patients with type 1 primary hyperoxaluria respond to pyridoxine—studies suggest that approximately 10 to 30 percent of patients may benefit from this therapy. Testing for pyridoxine responsiveness involves giving the vitamin for several months while carefully monitoring urinary oxalate levels. If oxalate excretion decreases significantly, the patient continues the therapy indefinitely. For those who do respond, pyridoxine represents a safe, relatively simple treatment that can substantially slow disease progression. For those who don’t respond, other treatment strategies become necessary.^[3]

Dietary modifications play a supporting role in treatment, though their impact is limited because primary hyperoxaluria results from internal overproduction of oxalate rather than dietary intake. Most experts recommend avoiding extremely high-oxalate foods such as spinach, rhubarb, nuts, chocolate, and certain teas, but these restrictions don’t need to be as strict as in other forms of hyperoxaluria. Ensuring adequate calcium intake is important because calcium binds oxalate in the intestines, reducing absorption. Limiting sodium and animal protein may also help reduce calcium excretion in urine. Vitamin C supplements should be avoided because the body converts vitamin C into oxalate.^[18]

Managing Kidney Stones and Their Complications

Despite conservative treatment, many people with primary hyperoxaluria continue to form kidney stones. These stones cause significant pain and can obstruct urine flow, leading to infections and progressive kidney damage. The frequency of stone formation varies widely—some patients experience multiple stone episodes per year, while others may have less frequent problems, especially if treatment is working well.^[21]

When stones cause symptoms or threaten kidney function, urological procedures become necessary. Smaller stones may pass spontaneously with aggressive hydration and pain management. Larger stones typically require intervention. Extracorporeal shock wave lithotripsy uses focused sound waves from outside the body to break stones into smaller pieces that can pass more easily. Ureteroscopy involves passing a thin scope through the urethra and bladder into the ureter to directly visualize and remove stones or break them apart with a laser. For larger or more complex stones, percutaneous nephrolithotomy may be needed—a procedure where the surgeon makes a small incision in the back to access the kidney directly and remove stones.^[12]

Survey data from patients with primary hyperoxaluria reveals the profound impact of recurrent stones and procedures. Many patients undergo dozens of interventions over their lifetime, with some requiring more than 50 procedures. Each procedure carries risks of infection, bleeding, and scar tissue formation, and recovery requires time away from normal activities. The unpredictability of when stones will form and cause problems creates ongoing anxiety and disruption to daily life.^[21]

Revolutionary RNA Interference Therapies in Clinical Use

The arrival of RNA interference (RNAi) therapies has transformed the treatment landscape for primary hyperoxaluria. These sophisticated medications work by targeting the genetic instructions inside liver cells, effectively “silencing” specific genes that contribute to oxalate overproduction. Unlike traditional medications that try to work around the problem, RNAi therapies directly address the underlying biochemical defect at the molecular level.^[9]

Lumasiran was the first RNAi therapy approved for primary hyperoxaluria type 1 and received authorization in the European Union and United States in 2020. This medication works by targeting the messenger RNA for an enzyme called glycolate oxidase. When this enzyme is blocked, the liver produces less of a compound called glyoxylate, which is the immediate precursor to oxalate. With less glyoxylate available, less oxalate gets produced. Lumasiran is administered as a subcutaneous injection (under the skin) once monthly initially, then every three months for maintenance.^[15]

Clinical trial results for lumasiran have been impressive. In a pivotal Phase 3 study involving patients aged 6 to 60 years with primary hyperoxaluria type 1, treatment with lumasiran resulted in normalization of urinary oxalate excretion in 52 percent of patients and near-normalization in 84 percent of patients after six months. Patients also experienced reductions in plasma oxalate concentration, which is particularly important for those with advanced kidney disease. The medication demonstrated a favorable safety profile, with the most common side effects being injection site reactions and abdominal pain.^[15]

Lumasiran is approved for use in both children and adults with primary hyperoxaluria type 1. It represents a particularly important option for patients who don’t respond to pyridoxine and for those with declining kidney function. By reducing oxalate production at its source in the liver, this therapy addresses the fundamental problem driving the disease. Patients taking lumasiran still need to maintain other aspects of their treatment regimen, including adequate hydration, but the dramatic reduction in oxalate burden offers hope for preserving kidney function and preventing systemic complications.^[9]

Nedosiran is another RNAi therapy that has been developed for primary hyperoxaluria. This medication works through a different mechanism than lumasiran—it targets lactate dehydrogenase A, the enzyme responsible for the final step in converting glyoxylate to oxalate. By blocking this last step, nedosiran prevents oxalate formation even when glyoxylate levels are elevated. Like lumasiran, nedosiran is given by subcutaneous injection. Clinical trials have shown that nedosiran can achieve substantial reductions in both urinary and plasma oxalate levels in patients with primary hyperoxaluria types 1 and 2.^[9]

The introduction of RNAi therapies has been described by many experts as a breakthrough comparable to the development of enzyme replacement therapies for other metabolic diseases. These medications offer the possibility of preventing disease progression when started early, potentially avoiding or delaying the need for transplantation. For patients who already have advanced kidney disease, RNAi therapies can reduce the burden of oxalate accumulation throughout the body, potentially preventing or slowing systemic oxalosis—the devastating complication where oxalate deposits in bones, heart, blood vessels, and other tissues.^[11]

Dialysis and Transplantation Options

When kidney function declines to the point of kidney failure—a condition called end-stage renal disease—patients with primary hyperoxaluria face particularly challenging circumstances. Standard dialysis treatments, whether peritoneal dialysis or conventional hemodialysis performed three times weekly, cannot remove oxalate fast enough to prevent its accumulation in the body. Because the liver continues to overproduce oxalate at a rapid rate, plasma oxalate levels rise dramatically once the kidneys can no longer excrete it.^[3]

When oxalate accumulates in the blood and tissues—a condition called systemic oxalosis—it causes severe complications. Oxalate crystals deposit in bones, causing fractures and debilitating bone pain. Deposits in the heart can lead to heart rhythm abnormalities and heart failure. Oxalate in blood vessel walls can cause circulation problems. The eyes, nerves, and skin can all be affected. Without intervention, systemic oxalosis is life-threatening.^[1]

Intensive hemodialysis regimens can help control oxalate levels better than standard schedules. Some patients receive dialysis six or seven days per week, or for longer sessions. This aggressive approach can slow the accumulation of oxalate but doesn’t eliminate it entirely. The physical and emotional toll of this frequency of dialysis is substantial, particularly for children, affecting growth, development, school attendance, and family life.^[3]

For many patients with primary hyperoxaluria type 1 who develop kidney failure, transplantation becomes necessary. However, because the underlying problem is in the liver—not the kidneys—a kidney transplant alone faces a high risk of failure. The new kidney would be exposed to the same excessive oxalate production that destroyed the original kidneys, potentially leading to rapid recurrence of disease and graft loss. For this reason, combined liver and kidney transplantation has traditionally been the recommended approach for patients with type 1 primary hyperoxaluria and kidney failure.^[3]

In a combined transplant, the new liver provides the functional enzyme that the patient lacks, correcting the metabolic defect and normalizing oxalate production. The new kidney then functions in an environment with normal oxalate levels. This approach has shown good long-term success rates. The transplants can be performed simultaneously or sequentially—liver first followed by kidney later, or occasionally kidney first with close monitoring and intensive dialysis, followed by liver transplant.^[12]

The arrival of RNAi therapies has changed the transplant landscape. Some patients with well-controlled oxalate production on medications like lumasiran may be candidates for kidney transplant alone, without requiring liver transplantation. This is an evolving area of practice, and decisions are made carefully on an individual basis. Liver transplantation is a major surgery with significant risks and requires lifelong immunosuppression to prevent rejection, so avoiding it when possible represents an important advantage.^[11]

Emerging Therapies and Future Treatment Directions

Beyond the RNAi therapies already in clinical use, researchers are actively investigating additional innovative approaches to treating primary hyperoxaluria. The goal of these efforts is to develop treatments that are even more effective, easier to administer, or applicable to more patients.^[9]

Small molecule substrate reduction therapy represents one promising direction. These are traditional medications that work by blocking specific enzymes in the oxalate production pathway, similar to how RNAi therapies work but using chemical compounds rather than genetic approaches. Small molecules might offer advantages in terms of oral administration rather than injection, potentially improving convenience for patients. Several compounds are in various stages of research and development.^[9]

Gene therapy approaches aim to permanently correct the genetic defect causing primary hyperoxaluria. Scientists are developing methods to deliver a functional copy of the defective gene into liver cells, potentially providing a one-time treatment that could cure the disease. Early research uses specialized viral vectors to carry the corrected gene into cells. While gene therapy has shown remarkable success for some other genetic diseases, applying it to primary hyperoxaluria faces technical challenges that researchers are working to overcome. This approach remains experimental but holds tremendous promise for the future.^[9]

Induced pluripotent stem cell therapy represents another cutting-edge approach. In this strategy, scientists take a patient’s own cells, reprogram them into stem cells, correct the genetic defect in the laboratory, then develop these corrected stem cells into liver-like cells that produce the functional enzyme. These corrected cells could then be transplanted back into the patient’s liver. This approach would avoid the need for finding a donor organ and would use the patient’s own genetic material, potentially reducing rejection risk. Research in this area is still in early stages.^[9]

Clinical trials are also investigating oxalate-degrading probiotics—beneficial bacteria that can break down oxalate in the intestines. A bacterium called Oxalobacter formigenes naturally colonizes the intestines of many healthy people and consumes oxalate as a food source. People with primary hyperoxaluria often lack this organism. Researchers are studying whether supplementing with these bacteria could help reduce the total oxalate burden by degrading some of it before absorption. While this approach wouldn’t address the liver overproduction problem, it might provide additional benefit when combined with other therapies.^[18]

Another area of active research involves crystallization inhibitors—substances that prevent oxalate and calcium from forming crystals even when both are present in high concentrations. Natural inhibitors exist in urine, and researchers are working to develop synthetic versions that might be more potent. Such therapies could potentially reduce stone formation and crystal deposition in kidneys and other tissues.^[11]

Most common treatment methods

• Conservative Management
  • Hyperhydration with very high fluid intake throughout day and night to dilute urinary oxalate concentration
  • Potassium citrate or pyrophosphate salts to inhibit calcium oxalate crystal formation
  • Pyridoxine (vitamin B6) in high doses for responsive patients with specific genetic mutations
  • Dietary modifications including limiting extremely high-oxalate foods and ensuring adequate calcium intake
  • Avoiding vitamin C supplements which can increase oxalate production
• RNA Interference Therapy
  • Lumasiran administered by subcutaneous injection monthly then quarterly to reduce liver oxalate production by targeting glycolate oxidase enzyme
  • Nedosiran given by subcutaneous injection to block lactate dehydrogenase A enzyme and prevent final conversion to oxalate
  • Both therapies can normalize or near-normalize urinary and plasma oxalate levels in many patients
• Urological Procedures
  • Extracorporeal shock wave lithotripsy using focused sound waves to fragment kidney stones
  • Ureteroscopy with laser lithotripsy to remove or break apart stones through natural urinary passages
  • Percutaneous nephrolithotomy for larger or complex stones requiring direct kidney access
• Dialysis
  • Intensive hemodialysis schedules (daily or extended sessions) to remove excess oxalate in patients with kidney failure
  • Required more frequently than standard dialysis to control plasma oxalate accumulation
• Transplantation
  • Combined liver and kidney transplantation to correct metabolic defect and replace damaged kidneys
  • Sequential transplantation with liver followed by kidney or reverse order depending on clinical situation
  • Kidney transplant alone potentially possible in some patients with well-controlled oxalate on RNAi therapy

Monitoring and Lifelong Follow-Up

People with primary hyperoxaluria require comprehensive monitoring throughout their lives, even when treatment appears to be working well. The frequency and intensity of monitoring depends on disease severity, kidney function, and treatment response. Regular assessments allow healthcare teams to detect problems early and adjust treatment before irreversible damage occurs.^[11]

Laboratory monitoring includes regular measurement of urinary oxalate excretion through 24-hour urine collections, assessment of kidney function through blood tests measuring creatinine and estimated glomerular filtration rate, and for those with advanced disease, plasma oxalate concentration. These tests show whether treatment is adequately controlling oxalate levels and whether kidney function remains stable. Adjustments to medication doses or treatment strategies may be needed based on these results.^[3]

Kidney ultrasound examinations are performed regularly to look for new kidney stones, monitor existing stones, and check for nephrocalcinosis—calcium oxalate crystal deposits within the kidney tissue itself. The presence and progression of nephrocalcinosis provides important information about disease control and prognosis. In some cases, additional imaging with CT scans may be needed for more detailed evaluation.^[11]

For patients with advanced kidney disease or those on dialysis, monitoring for systemic oxalosis becomes critical. This includes bone density assessments to detect oxalate-related bone disease, eye examinations to identify retinal oxalate deposits, electrocardiograms and echocardiograms to evaluate heart function, and attention to symptoms that might indicate oxalate deposits in nerves or other tissues. Early detection of systemic involvement allows for intensification of treatment to prevent further damage.^[3]

Living with Primary Hyperoxaluria: Daily Challenges and Support

Beyond the medical treatments and procedures, living with primary hyperoxaluria affects every aspect of daily life. The constant need for hyperhydration means carrying water bottles everywhere, planning activities around bathroom access, and coping with interrupted sleep from nighttime urination. Children may feel different from peers, unable to participate fully in sleepovers, camps, or school trips. Adults struggle to balance work responsibilities with frequent medical appointments and unpredictable stone episodes.^[21]

The emotional and psychological impact of primary hyperoxaluria can be profound. Living with a rare disease that most people—including many healthcare providers—have never heard of creates feelings of isolation. The unpredictability of when stones will form or when kidney function might decline generates ongoing anxiety. Parents of affected children carry the dual burden of managing complex medical care while helping their child navigate the social and emotional challenges of chronic illness.^[17]

Research has shown that people with chronic kidney disease, including those with primary hyperoxaluria, have elevated rates of depression and anxiety. These mental health challenges can affect adherence to treatment, overall quality of life, and disease outcomes. Recognizing and addressing psychological needs is an important part of comprehensive care. Mental health support through counseling, support groups, and in some cases medication can help patients and families cope more effectively.^[22]

Patient advocacy organizations play a crucial role in supporting those affected by primary hyperoxaluria. The Oxalosis and Hyperoxaluria Foundation and similar organizations worldwide provide educational resources, connect patients and families with each other, fund research, and advocate for improved care and access to treatments. Many families describe finding the patient community as a turning point, finally connecting with others who truly understand their experience.^[17]

Building a strong support system makes an enormous difference. This includes the medical team, certainly, but also family, friends, school personnel, employers, and the broader community of people affected by primary hyperoxaluria. Open communication about needs and limitations helps others understand and provide appropriate support. Many patients and caregivers find that sharing their story and educating others about this rare disease brings both personal meaning and practical benefits.^[19]

Despite the challenges, many people with primary hyperoxaluria live full, meaningful lives. Advances in treatment—particularly the arrival of RNAi therapies—have dramatically improved the outlook for patients diagnosed today compared to even a decade ago. With appropriate treatment started early, many patients can preserve kidney function, avoid or minimize stone complications, and participate actively in education, careers, relationships, and the activities they value. The combination of expert medical care, effective treatments, and strong support systems makes this possible.^[22]